Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS: Rivaroxaban for Prevention of Major Cardiovascular Events in CAD/PAD
NCT01776424Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 33
01
Overview
A Phase 3 trial of rivaroxaban in coronary artery disease (CAD), peripheral artery disease (PAD), sponsored by Bayer. Started Feb 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT01776424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01776424.